FDA has approved Viridian Therapeutics’ Lumvoa (veligrotug-vvze) for thyroid eye disease (TED), giving the company a new branded option for both chronic and active phases of the disorder. The therapy is designed to compete in a market previously dominated by Amgen’s Tepezza (teprotumumab-trbw), which was the only approved treatment after its January 2020 approval. The clearance, reported by company and FDA-facing coverage, includes labeling for chronic as well as active TED, along with dosing described as requiring fewer infusions. Viridian’s competitive positioning matters for patients who need long-term disease control and for payers assessing comparative burden and administration schedules. Separately, additional coverage reiterates the expected practical differentiators of Lumvoa versus Tepezza, including an emphasis on fast and durable effects and the implications of targeting an IGF-1R pathway in TED. Together, the items show a direct regulatory and commercial step into an established specialty ophthalmology niche.